Topic

Damien O’Brien is the vice president of life sciences for IDA Ireland, the Irish government’s foreign direct investment agency

Articles

Recent growth in pharma makes Ireland an ideal candidate for expansion opportunities.

Three Keys to Ireland’s Resilient Pharma Industry

The risky business of outmaneuvering Europe’s drug pricing authorities.

Can Pharma Seize the High Ground in Latest Pricing Proposal Flurry?

Managing director, in-house counsel practice, Major, Lindsey & Africa

Brexit and the pandemic continue to complicate flow of international talent.

It’s Time to Get Creative Hiring in a Post-Brexit European Life Sciences Market

Fresh round of discussions around health technology assessment.

Europe’s New HTA System Spurs More Debate, Concern

Witkos discusses her achievements during her first year as SVP, International Region head, and her long-term goals in helping to maintain Alnylam’s leadership in the RNAi field.

Q&A with Kasha Witkos, SVP, head of International Region, Alnylam Pharmaceuticals 

Brian Kwak is a director within the life sciences practice at Guidehouse

Karina Ikeda is a senior consultant within the life sciences practice at Guidehouse

Natalya Stone is a consultant within the life sciences practice at Guidehouse

Opportunity remains despite regulatory and access obstacles.

The JAKs Journey Offers Valuable Lessons for Innovators

Emma Thorp and Mel Walker, PhD, of RBW consulting discuss European strategy for US biotechs.

Why Now Could Be the Right Time to Reconsider Your Planning For Europe Strategy

European Commission looks to relieve issues without legislation.

EU Steps in on Pricing, Offers Member States Aid to Negotiate

Paul Gershlick is Chair of PING and Partner and Head of Pharmaceuticals and Life Sciences at VWV Watford.

2021‘s Pharmaceutical Industry Network Group (PING) conference focused on the UK’s COVID-19 response and how it can continue as a leader in science innovation and collaboration, including opportunities through use of health and genomic data.









Cultivating UK Life Sciences Collaboration and Innovation

Novo Nordisk announces plans to invest more than 17bn Danish kroner constructing three new manufacturing facilities in Kalundborg, Denmark.​